Lifecare ASA: Mandatory notification of trade

12 Jun 2024 10:58 CEST

Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 30 May 2024, regarding the commencement of the subscription
period in the partially underwritten rights issue (the "Rights Issue").

Hannibal Invest AS, a company closely associated with Hans Hekland, member of
the board of directors of, and primary insider in, the Company, has today
subscribed 21,888 shares in the Rights Issue at a price of NOK 1.52442 per
share. Please see the attached PDMR-form for further details.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-06-12 10:58 CEST.

More information:
Access the news on Oslo Bors NewsWeb site

621254_Lifecare ASA- Mandatory notification of trade.pdf
621254_240612 PDMR Attachment.pdf